Health CanadaGeneral Alert
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (niloti...
Published: May 4, 2016Recall ID: 55251Category: generalCountry: Canada
Reason for Recall / Hazard
Product safety
Product Description & Identification
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
Additional Source Details
| Field | Value |
|---|---|
| N I D | 55251 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/bcr-abl-tyrosine-kinase-inhibitors-gleevec-imatinib-mesylate-tasigna-nilotinib-bosulif |
| Issue | Product safety |
| Title | BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation |
| Archived | 1 |
| Category | Drugs |
| Last updated | 2016-05-04 |
| Organization | Marketed health products |